Skip to main content
Top
Published in: Journal of Thrombosis and Thrombolysis 1/2015

Open Access 01-07-2015

Inflammatory response and pneumocyte apoptosis during lung ischemia–reperfusion injury in an experimental pulmonary thromboembolism model

Authors: Chaosheng Deng, Zhenguo Zhai, Dawen Wu, Qichang Lin, Yuanhua Yang, Minxia Yang, Haibo Ding, Xiaoming Cao, Qiaoxian Zhang, Chen Wang

Published in: Journal of Thrombosis and Thrombolysis | Issue 1/2015

Login to get access

Abstract

Lung ischemia–reperfusion injury (LIRI) may occur in the region of the affected lung after reperfusion therapy. The inflammatory response mechanisms related to LIRI in pulmonary thromboembolism (PTE), especially in chronic PTE, need to be studied further. In a PTE model, inflammatory response and apoptosis may occur during LIRI and nitric oxide (NO) inhalation may alleviate the inflammatory response and apoptosis of pneumocytes during LIRI. A PTE canine model was established through blood clot embolism to the right lower lobar pulmonary artery. Two weeks later, we performed embolectomy with reperfusion to examine the LIRI changes among different groups. In particular, the ratio of arterial oxygen partial pressure to fractional inspired oxygen (PaO2/FiO2), serum concentrations of tumor necrosis factor-α (TNF-α), myeloperoxidase concentrations in lung homogenates, alveolar polymorphonuclear neutrophils (PMNs), lobar lung wet to dry ratio (W/D ratio), apoptotic pneumocytes, and lung sample ultrastructure were assessed. The PaO2/FiO2 in the NO inhalation group increased significantly when compared with the reperfusion group 4 and 6 h after reperfusion (368.83 ± 55.29 vs. 287.90 ± 54.84 mmHg, P < 0.05 and 380.63 ± 56.83 vs. 292.83 ± 6 0.34 mmHg, P < 0.05, respectively). In the NO inhalation group, TNF-α concentrations and alveolar PMN infiltration were significantly decreased as compared with those of the reperfusion group, 6 h after reperfusion (7.28 ± 1.49 vs. 8.90 ± 1.43 pg/mL, P < 0.05 and [(19 ± 6)/10 high power field (HPF) vs. (31 ± 11)/10 HPF, P < 0.05, respectively]. The amount of apoptotic pneumocytes in the lower lobar lung was negatively correlated with the arterial blood PaO2/FiO2, presented a positive correlation trend with the W/D ratio of the lower lobar lung, and a positive correlation with alveolar PMN in the reperfusion group and NO inhalation group. NO provided at 20 ppm for 6 h significantly alleviated LIRI in the PTE model. Our data indicate that, during LIRI, an obvious inflammatory response and apoptosis occur in our PTE model and NO inhalation may be useful in treating LIRI by alleviating the inflammatory response and pneumocyte apoptosis. This potential application warrants further investigation.
Literature
1.
go back to reference Chesnutt MS, Prendergast TJ, McPhee SJ, Papadakis MA, Tierney LM Jr (2007) Pulmonary venous thromboembolism. Current medical diagnosis and treatment, 46th edn. McGraw-Hill, New York, pp 284–294 Chesnutt MS, Prendergast TJ, McPhee SJ, Papadakis MA, Tierney LM Jr (2007) Pulmonary venous thromboembolism. Current medical diagnosis and treatment, 46th edn. McGraw-Hill, New York, pp 284–294
5.
go back to reference Moriyama K, Sugiyama S, Uzawa K, Kotani M, Satoh T, Yorozu T (2011) Noninvasive positive pressure ventilation against reperfusion pulmonary edema following percutaneous transluminal pulmonary angioplasty. Case Rep Anesthesiol. 2011:204538. doi:10.1155/2011/204538 PubMedCentralPubMed Moriyama K, Sugiyama S, Uzawa K, Kotani M, Satoh T, Yorozu T (2011) Noninvasive positive pressure ventilation against reperfusion pulmonary edema following percutaneous transluminal pulmonary angioplasty. Case Rep Anesthesiol. 2011:204538. doi:10.​1155/​2011/​204538 PubMedCentralPubMed
6.
go back to reference Puis L, Vandezande E, Vercaemst L, Janssens P, Taverniers Y, Foulon M, Demeyere R, Delcroix M, Daenen W (2005) Pulmonary thromboendarterectomy for chronic thromboembolic pulmonary hypertension. Perfusion. 20:101–108. doi:10.1191/0267659105pf791oa CrossRefPubMed Puis L, Vandezande E, Vercaemst L, Janssens P, Taverniers Y, Foulon M, Demeyere R, Delcroix M, Daenen W (2005) Pulmonary thromboendarterectomy for chronic thromboembolic pulmonary hypertension. Perfusion. 20:101–108. doi:10.​1191/​0267659105pf791o​a CrossRefPubMed
10.
go back to reference Gan HL, Zhang JQ, Bo P, Zhou QW, Wang SX (2010) The actuarial survival analysis of the surgical and non-surgical therapy regimen for chronic thromboembolic pulmonary hypertension. J Thromb Thrombolysis 29:5–31. doi:10.1007/s11239-0090319-1 CrossRef Gan HL, Zhang JQ, Bo P, Zhou QW, Wang SX (2010) The actuarial survival analysis of the surgical and non-surgical therapy regimen for chronic thromboembolic pulmonary hypertension. J Thromb Thrombolysis 29:5–31. doi:10.​1007/​s11239-0090319-1 CrossRef
13.
15.
go back to reference Hosokawa K, Ishibashi-Ueda H, Kishi T, Nakanishi N, Kyotani S, Ogino H (2011) Histopathological multiple recannalized lesion is critical element of outcome after pulmonary thromboendarteretomy. Int Heart J 52:377–381. doi:10.1536/ihj.52.377 CrossRefPubMed Hosokawa K, Ishibashi-Ueda H, Kishi T, Nakanishi N, Kyotani S, Ogino H (2011) Histopathological multiple recannalized lesion is critical element of outcome after pulmonary thromboendarteretomy. Int Heart J 52:377–381. doi:10.​1536/​ihj.​52.​377 CrossRefPubMed
16.
go back to reference Jamieson SW, Kapelanski DP, Sakakibara N, Manecke GR, Thistlethwaite PA, Kerr KM, Channick RN, Fedullo PF, Auger WR (2003) Pulmonary endarterectomy: experience and lessons learned in 1,500 cases. Ann Thorac Surg 76:1457–1464. doi:10.1016/S0003-4975(03)00828-2 CrossRefPubMed Jamieson SW, Kapelanski DP, Sakakibara N, Manecke GR, Thistlethwaite PA, Kerr KM, Channick RN, Fedullo PF, Auger WR (2003) Pulmonary endarterectomy: experience and lessons learned in 1,500 cases. Ann Thorac Surg 76:1457–1464. doi:10.​1016/​S0003-4975(03)00828-2 CrossRefPubMed
17.
go back to reference Kerr KM, Auger WR, Marsh JJ, Comito RM, Fedullo RL, Smits GJ, Kapelanski DP, Fedullo PF, Channick RN, Jamieson SW, Moser KM (2000) The use of cylexin (CY-1503) in prevention of reperfusion lung injury in patients undergoing pulmonary thromboendarterectomy. Am J Respir Crit Care Med 162:14–20. doi:10.1164/ajrccm.162.1.9712142 CrossRefPubMed Kerr KM, Auger WR, Marsh JJ, Comito RM, Fedullo RL, Smits GJ, Kapelanski DP, Fedullo PF, Channick RN, Jamieson SW, Moser KM (2000) The use of cylexin (CY-1503) in prevention of reperfusion lung injury in patients undergoing pulmonary thromboendarterectomy. Am J Respir Crit Care Med 162:14–20. doi:10.​1164/​ajrccm.​162.​1.​9712142 CrossRefPubMed
24.
go back to reference Van Golen RF, Reiniers MJ, Olthof PB, van Gulik TM, Heger M (2013) Sterile inflammation in hepatic ischemia/reperfusion injury: present concepts and potential therapeutics. J Gastroenterol Hepatol 28:394–400. doi:10.1111/jgh.12072 CrossRefPubMed Van Golen RF, Reiniers MJ, Olthof PB, van Gulik TM, Heger M (2013) Sterile inflammation in hepatic ischemia/reperfusion injury: present concepts and potential therapeutics. J Gastroenterol Hepatol 28:394–400. doi:10.​1111/​jgh.​12072 CrossRefPubMed
26.
go back to reference Prakash A, Mesa KR, Wilhelmsen K, Dodd-o JM, Hellman J (2012) Alveolar macrophages and Toll-like receptor 4 mediate ventilated lung ischemia reperfusion injury in mice. Anesthesiology 117:822–835CrossRefPubMedCentralPubMed Prakash A, Mesa KR, Wilhelmsen K, Dodd-o JM, Hellman J (2012) Alveolar macrophages and Toll-like receptor 4 mediate ventilated lung ischemia reperfusion injury in mice. Anesthesiology 117:822–835CrossRefPubMedCentralPubMed
27.
go back to reference Soehnlein O, Lindbom L (2010) Phagocyte partnership during the onset and resolution of inflammation. Nat Rev Immunol 10:427–439CrossRefPubMed Soehnlein O, Lindbom L (2010) Phagocyte partnership during the onset and resolution of inflammation. Nat Rev Immunol 10:427–439CrossRefPubMed
28.
go back to reference Albrecht C, Schins RP, Hohr D, Becker A, Shi T, Knaapen AM, Borm PJ (2004) Inflammatory time course after quartz instillation: role of tumor necrosis factor-alpha and particle surface. Am J Respir Cell Mol Biol 31:292–301. doi:10.1165/rcmb.2003-0300OC CrossRefPubMed Albrecht C, Schins RP, Hohr D, Becker A, Shi T, Knaapen AM, Borm PJ (2004) Inflammatory time course after quartz instillation: role of tumor necrosis factor-alpha and particle surface. Am J Respir Cell Mol Biol 31:292–301. doi:10.​1165/​rcmb.​2003-0300OC CrossRefPubMed
30.
31.
34.
go back to reference Deng Chaosheng, Yang Minxia, Lin Qichang, Yang Yuanhua, Zhai Zhenguo, Liu Kaixiong, Ding Haibo, Cao Xiaoming, Huang Zhihua, Zhang Lina, Zhao Jianming (2014) Beneficial effects of inhaled NO on apoptotic pneumocytes in pulmonary thromboembolism model. Theor Biol Med Model. doi:10.1186/1742-4682-11-36 PubMedCentralPubMed Deng Chaosheng, Yang Minxia, Lin Qichang, Yang Yuanhua, Zhai Zhenguo, Liu Kaixiong, Ding Haibo, Cao Xiaoming, Huang Zhihua, Zhang Lina, Zhao Jianming (2014) Beneficial effects of inhaled NO on apoptotic pneumocytes in pulmonary thromboembolism model. Theor Biol Med Model. doi:10.​1186/​1742-4682-11-36 PubMedCentralPubMed
36.
go back to reference Szold O, Khoury W, Biderman P, Klausner JM, Halpern P, Weinbroum AA (2006) Inhaled nitric oxide improves pulmonary functions following massive pulmonary embolism: a report of four patients and review of the literature. Lung 184:1–5. doi:10.1007/s00408-005-2550-7 CrossRefPubMed Szold O, Khoury W, Biderman P, Klausner JM, Halpern P, Weinbroum AA (2006) Inhaled nitric oxide improves pulmonary functions following massive pulmonary embolism: a report of four patients and review of the literature. Lung 184:1–5. doi:10.​1007/​s00408-005-2550-7 CrossRefPubMed
38.
go back to reference Suntharalingam J, Hughes RJ, Goldsmith K, Doughty N, George P, Toshner M, Sheares KK, Pepke-Zaba J (2007) Acute haemodynamic responses to inhaled nitric oxide and intravenous sildenafil in distal chronic thromboembolic pulmonary hypertension (CTEPH). Vascul Pharmacol 46:449–455. doi:10.1016/j.vph.2007.01.008 CrossRefPubMed Suntharalingam J, Hughes RJ, Goldsmith K, Doughty N, George P, Toshner M, Sheares KK, Pepke-Zaba J (2007) Acute haemodynamic responses to inhaled nitric oxide and intravenous sildenafil in distal chronic thromboembolic pulmonary hypertension (CTEPH). Vascul Pharmacol 46:449–455. doi:10.​1016/​j.​vph.​2007.​01.​008 CrossRefPubMed
39.
go back to reference Pastva AM, Walker JK, Maddox LA, Mukherjee S, Giamberardino C, Hsia B, Potts E, Zhu H, Degan S, Sunday ME, Lawson BL, Korfhagen TR, Schwartz DA, Eu JP, Foster WM, McMahon TJ, Que L, Wright JR (2011) Nitric oxide mediates relative airway hyporesponsiveness to lipopolysaccharide in surfactant protein A-deficient mice. Am J Respir Cell Mol Biol 44:175–184. doi:10.1165/rcmb-0284OC CrossRefPubMedCentralPubMed Pastva AM, Walker JK, Maddox LA, Mukherjee S, Giamberardino C, Hsia B, Potts E, Zhu H, Degan S, Sunday ME, Lawson BL, Korfhagen TR, Schwartz DA, Eu JP, Foster WM, McMahon TJ, Que L, Wright JR (2011) Nitric oxide mediates relative airway hyporesponsiveness to lipopolysaccharide in surfactant protein A-deficient mice. Am J Respir Cell Mol Biol 44:175–184. doi:10.​1165/​rcmb-0284OC CrossRefPubMedCentralPubMed
42.
go back to reference Zheng ZK, Wang JJ, Hu H, Jiang K, Nie J, Zhang J, Guo H, Qiao XW, Li JS (2013) Short-term inhalation of nitric oxide inhibits activations of toll-like receptor 2 and 4 in the lung after ischemia-reperfusion injury in mice. J Huazhong Univ Sci Technol Med Sci. 33:219–223. doi:10.1007/s11596-013-1100-4 CrossRefPubMed Zheng ZK, Wang JJ, Hu H, Jiang K, Nie J, Zhang J, Guo H, Qiao XW, Li JS (2013) Short-term inhalation of nitric oxide inhibits activations of toll-like receptor 2 and 4 in the lung after ischemia-reperfusion injury in mice. J Huazhong Univ Sci Technol Med Sci. 33:219–223. doi:10.​1007/​s11596-013-1100-4 CrossRefPubMed
43.
go back to reference Waldow T, Witt W, Janke A, Ulmer A, Buzin A, Matschke K (2009) Cell-cell junctions and vascular endothelial growth factor in rat lung as affected by ischemia/reperfusion and preconditioning with inhaled nitric oxide. J Surg Res 157:30–42. doi:10.1016/j.jss.2008.07.042 CrossRefPubMed Waldow T, Witt W, Janke A, Ulmer A, Buzin A, Matschke K (2009) Cell-cell junctions and vascular endothelial growth factor in rat lung as affected by ischemia/reperfusion and preconditioning with inhaled nitric oxide. J Surg Res 157:30–42. doi:10.​1016/​j.​jss.​2008.​07.​042 CrossRefPubMed
44.
go back to reference Bolli R (2001) Cardioprotective function of inducible nitric oxide synthase and role of nitric oxide in myocardial ischemia and preconditioning: an overview of a decade of research. J Mol Cell Cardiol 33:1897–1918. doi:10.1006/jmcc.2001.1462 CrossRefPubMed Bolli R (2001) Cardioprotective function of inducible nitric oxide synthase and role of nitric oxide in myocardial ischemia and preconditioning: an overview of a decade of research. J Mol Cell Cardiol 33:1897–1918. doi:10.​1006/​jmcc.​2001.​1462 CrossRefPubMed
45.
go back to reference Sugimoto R, Okamoto T, Nakao A, Zhan J, Wang Y, Kohmoto J, Tokita D, Farver CF, Tarpey MM, Billiar TR, Gladwin MT, McCurry KR (2012) Nitrite reduces acute lung injury and improves survival in a rat lung transplantation model. Am J Transplant 12:2938–2948. doi:10.1111/j.1600-6143,2012.04169.x CrossRefPubMed Sugimoto R, Okamoto T, Nakao A, Zhan J, Wang Y, Kohmoto J, Tokita D, Farver CF, Tarpey MM, Billiar TR, Gladwin MT, McCurry KR (2012) Nitrite reduces acute lung injury and improves survival in a rat lung transplantation model. Am J Transplant 12:2938–2948. doi:10.​1111/​j.​1600-6143,2012.​04169.​x CrossRefPubMed
46.
go back to reference Sitbon O, Brenot F, Denjean A, Bergeron A, Parent F, Azarian R, Herve P, Raffestin B, Simonneau G (1995) Inhaled nitric oxide as a screening vasodilator agent in primary pulmonary hypertension: adose-response study and comparison with prostacyclin. Am J Respir Crit Care Med 151:384–389. doi:10.1164/ajrccm.151.2.7842196 CrossRefPubMed Sitbon O, Brenot F, Denjean A, Bergeron A, Parent F, Azarian R, Herve P, Raffestin B, Simonneau G (1995) Inhaled nitric oxide as a screening vasodilator agent in primary pulmonary hypertension: adose-response study and comparison with prostacyclin. Am J Respir Crit Care Med 151:384–389. doi:10.​1164/​ajrccm.​151.​2.​7842196 CrossRefPubMed
47.
go back to reference Hagl C, Khaladj N, Peters T, Hoeper MM, Logemann F, Haverich A, Macchiarini P (2003) Technical advances of pulmonary thromboendarterectomy for chronic thromboembolic pulmonary hypertension. Eur J Cardiothorac Surg 23:776–781. doi:10.1016/S1010-7940(03)00029-0 CrossRefPubMed Hagl C, Khaladj N, Peters T, Hoeper MM, Logemann F, Haverich A, Macchiarini P (2003) Technical advances of pulmonary thromboendarterectomy for chronic thromboembolic pulmonary hypertension. Eur J Cardiothorac Surg 23:776–781. doi:10.​1016/​S1010-7940(03)00029-0 CrossRefPubMed
Metadata
Title
Inflammatory response and pneumocyte apoptosis during lung ischemia–reperfusion injury in an experimental pulmonary thromboembolism model
Authors
Chaosheng Deng
Zhenguo Zhai
Dawen Wu
Qichang Lin
Yuanhua Yang
Minxia Yang
Haibo Ding
Xiaoming Cao
Qiaoxian Zhang
Chen Wang
Publication date
01-07-2015
Publisher
Springer US
Published in
Journal of Thrombosis and Thrombolysis / Issue 1/2015
Print ISSN: 0929-5305
Electronic ISSN: 1573-742X
DOI
https://doi.org/10.1007/s11239-015-1182-x

Other articles of this Issue 1/2015

Journal of Thrombosis and Thrombolysis 1/2015 Go to the issue
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine